FOREST LABORATORIES, ALMIRALL ENTER INTO DEAL TO COLLABORATE ON DEVELOPMENT AND MARKETING OF NEW COPD DRUG

Monday morning, Forest Laboratories Inc., a New-York based pharmaceutical company, revealed that its subsidiary, Forest Laboratories Holdings Ltd., entered into a deal with Almirall, a Spain-based pharmaceutical company for the joint development and distribution of Almirall-developed, inhaled, long-acting muscarinic antagonist, LAS34273, in the United States.
Trading Markets